- Home
- DSL vs ARVN Comparison
DSL vs ARVN Comparison
Compare DSL & ARVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DSL
- ARVN
- Stock Information
- Founded
- DSL 2013
- ARVN 2015
- Country
- DSL United States
- ARVN United States
- Employees
- DSL N/A
- ARVN N/A
- Industry
- DSL Trusts Except Educational Religious and Charitable
- ARVN Biotechnology: Pharmaceutical Preparations
- Sector
- DSL Finance
- ARVN Health Care
- Exchange
- DSL Nasdaq
- ARVN Nasdaq
- Market Cap
- DSL 1.4B
- ARVN 1.4B
- IPO Year
- DSL N/A
- ARVN 2018
- Fundamental
- Price
- DSL $12.71
- ARVN $18.00
- Analyst Decision
- DSL
- ARVN Strong Buy
- Analyst Count
- DSL 0
- ARVN 12
- Target Price
- DSL N/A
- ARVN $60.70
- AVG Volume (30 Days)
- DSL 412.7K
- ARVN 800.2K
- Earning Date
- DSL 01-01-0001
- ARVN 02-11-2025
- Dividend Yield
- DSL 10.30%
- ARVN N/A
- EPS Growth
- DSL N/A
- ARVN N/A
- EPS
- DSL N/A
- ARVN N/A
- Revenue
- DSL N/A
- ARVN $161,100,000.00
- Revenue This Year
- DSL N/A
- ARVN $239.85
- Revenue Next Year
- DSL N/A
- ARVN N/A
- P/E Ratio
- DSL N/A
- ARVN N/A
- Revenue Growth
- DSL N/A
- ARVN 1.07
- 52 Week Low
- DSL $10.22
- ARVN $16.61
- 52 Week High
- DSL $12.96
- ARVN $53.08
- Technical
- Relative Strength Index (RSI)
- DSL 56.39
- ARVN 36.64
- Support Level
- DSL $12.50
- ARVN $17.46
- Resistance Level
- DSL $12.79
- ARVN $18.57
- Average True Range (ATR)
- DSL 0.09
- ARVN 0.97
- MACD
- DSL 0.02
- ARVN 0.08
- Stochastic Oscillator
- DSL 72.58
- ARVN 18.22
About DSL DoubleLine Income Solutions Fund of Beneficial Interests
DoubleLine Income Solutions Fund is a closed-end management investment company. Its primary investment objective is to seek high income and its secondary objective is to seek capital appreciation. It invests in debt securities and other income-producing investments anywhere in the world, including emerging markets. The company's investment portfolio comprises foreign corporate bonds, U.S. corporate bonds, bank loans, collateralized loan obligations, non-agency commercial mortgage backed obligations, asset-backed obligations, and municipal bonds among others.
About ARVN Arvinas Inc.
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.